9-Phenyl-9H-Carbazol-3-Ylboronic Acid | CAS:854952-58-2

We serve 9-Phenyl-9H-Carbazol-3-Ylboronic Acid CAS:854952-58-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
9-Phenyl-9H-Carbazol-3-Ylboronic Acid

Chemical Name:9-Phenyl-9H-Carbazol-3-Ylboronic Acid
CAS.NO:854952-58-2
Synonyms:(9-phenylcarbazol-3-yl)boronic acid
Molecular Formula:C18H14BNO2
Molecular Weight:287.12000
 
Physical and Chemical Properties:
Density:1.2
Boiling point:466ºC
Flash point:235.6ºC
 
Specification:
Appearance:Off-white powder
Assay:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates



Contact us for information like 9-Phenyl-9H-Carbazol-3-Ylboronic Acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(9-phenylcarbazol-3-yl)boronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,9-Phenyl-9H-Carbazol-3-Ylboronic Acid Use and application,9-Phenyl-9H-Carbazol-3-Ylboronic Acid technical grade,usp/ep/jp grade.


Related News: Further research on Oligomannate’s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement.4-Chloro-1,2-diaminobenzene manufacturer Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.trans-N,N'-dimethylcyclohexane-1,2-diamine supplier Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.cyclohexane-1,3-dione vendor A key publication in a preclinical model demonstrated rigosertib’s ability to block cellular signaling by targeting RAS effector pathways (Divakar, S.K., et al., 2016: “A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.” Cell 165, 643).The US National Institutes of Health is working on a preventative vaccine, but it will likely take a few months until the first phase of clinical trials get underway, and more than a year until a vaccine might be available, according to experts.